About EXACT Therapeutics AS

Company Description

We are EXACT Therapeutics AS (“EXACT-Tx”), a clinical-stage biopharmaceutical company developing a novel ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®).

ACT® is a unique approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions.

EXACT Therapeutics and our ACT® platform builds on decades of R&D efforts within ultrasound and microbubbles performed by the former world leading diagnostic company; Nycomed Imaging AS (now GE Healthcare). In the late 1990’s and early 2000’s the core technology behind ACT® was developed, with more than $10 M and 40 man-years invested into establishing formulation, manufacturing line, quality control etc.

Year founded

2012

Served area

Worldwide

Shareholder information

Shares outstanding

29,997,219

IPO

July 14, 2020

Stock exchange(s)

Euronext Oslo

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.